One-hour postload hyperglycemia is a stronger predictor of type 2 diabetes than impaired fasting glucose

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages 3744-3751

  Fiorentino, Teresa Vanessa ^a   Marini, Maria Adelaide ^b   Andreozzi, Francesco ^a   Arturi, Franco ^a   Succurro, Elena ^a   Perticone, Maria ^a   Sciacqua, Angela ^a   Hribal, Marta Letizia ^a   Perticone, Francesco ^a   Sesti, Giorgio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; MIDDLE AGED; PHYSIOLOGY;

ADULT; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 84943785802     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2573     Document Type: Article

References (33)

1. International Diabetes Federation. IDF diabetes atlas. 6th ed. Brussels, Belgium: International Diabetes Federation, 2013. Available from: http://www.idf.org/diabetesatlas.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: The STOPNIDDM randomised trial. Lancet. 2002;359:2072-2077.
4. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
5. Chiasson JL, JosseRG,Gomis R, HanefeldM,Karasik A, LaaksoM. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOPNIDDM trial. JAMA 2003;290:486-494.
6. Ratner R, Goldberg R, Haffner S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888-894.
7. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance: Implications for care. Diabetes Care. 2007;30:753-759.
8. International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-1334.
9. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2015;38 (Suppl1):S8-S16.
10. Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting Glucose. Diabetes Care. 2006;29:1130-1139.
11. Laakso M, Zilinskaite J, Hansen T, et al. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. Diabetologia. 2008;51:502-511.
12. Abdul-Ghani MA, Abdul-Ghani T, Ali N, Defronzo RA. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008; 31:1650-1655.
13. Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study. Diabetes Care. 2009;32:281-286.
14. Priya M, Anjana RM, Chiwanga FS, Gokulakrishnan K, Deepa M, Mohan V. 1-hour venous plasma glucose and incident prediabetes and diabetes in Asian Indians. Diabetes Technol Ther. 2013;15: 497-502.
15. Succurro E, Marini MA, Arturi F, et al. Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis. 2009;207: 245-249.
16. Succurro E, Arturi F, Lugarà M, et al. One-hour postload plasma glucose levels are associated with kidney dysfunction. Clin J AmSoc Nephrol. 2010;5:1922-1927.
17. Sciacqua A, Miceli S, Carullo G, et al. One-hour postload plasma glucose levels and left ventricular mass in hypertensive patients. Diabetes Care. 2011;34:1406-1411.
18. Sciacqua A, Miceli S, Greco L, et al. One-hour postload plasma glucose levels and diastolic function in hypertensive patients. Diabetes Care. 2011;34:2291-2296.
19. Marini MA, Succurro E, Frontoni S, et al. Insulin sensitivity,-cell function, and incretin effect in individuals with elevated 1-hour postload plasma glucose levels. Diabetes Care. 2012;35:868-872.
20. Perticone F, Sciacqua A, Perticone M, et al. Serum uric acid and 1-h postload glucose in essential hypertension. Diabetes Care. 2012;35: 153-157.
21. Sciacqua A, Maio R, Miceli S, et al. Association between one-hour post-load plasma glucose levels and vascular stiffness in essential hypertension. PLoS One. 2012;7:e44470.
22. Marini MA, Frontoni S, Succurro E, et al. Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One. 2013;8:e77440.
23. Sciacqua A, Perticone M, Grillo N, et al. Vitamin D and 1-hour post-load plasma glucose in hypertensive patients. Cardiovasc Diabetol. 2014;13:48.
24. Sesti G, Fiorentino TV, Succurro E, et al. Elevated 1-h post-load plasma glucose levels in subjects with normal glucose tolerance are associated with unfavorable inflammatory profile. Acta Diabetol. 2014;51:927-932.
25. Sesti G, Hribal ML, Fiorentino TV, Sciacqua A, Perticone F. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diab Res Care. 2014;2:e000016.
26. Bianchi C, Miccoli R, Trombetta M, et al. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired-cell function, insulin resistance, and worse cardiovascular risk profile: The GENFIEV study. J Clin Endocrinol Metab. 2013;98:2100-2105.
27. Marini MA, Frontoni S, Mineo D, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab. 2003;88:3368-3371.
28. WHO Expert Committee on Diabetes Mellitus: Second report. World Health Organ Tech Rep Ser. 1980;646:1-80.
29. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007;30: 1544-1548.
30. Manco M, Panunzi S, Macfarlane DP, et al. One-hour plasma glucose identifies insulin resistance and beta-cell dysfunction in individuals with normal glucose tolerance: Cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study. Diabetes Care. 2010;33:2090-2097.
31. Alyass A, Almgren P, Akerlund M, et al. Modelling of OGTT curve identifies 1 h plasma glucose level as a strong predictor of incident type 2 diabetes: Results from two prospective cohorts. Diabetologia. 2015;58:87-97.
32. Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle interventions for patients with and at risk for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159:543-551.
33. Saito T, Watanabe M, Nishida J, et al. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: A randomized controlled trial. Arch Intern Med. 2001;171:1352-1360.